SLNO Stock Plummets 26% on Safety Concerns: Class Action Lawsuit Filed Against Soleno Therapeutics
Soleno Therapeutics faces securities fraud lawsuit over alleged safety misstatements in DCCR clinical trial. Stock fell 26% following August short-seller report.
SLNOsecurities fraudclass action lawsuit